Null and replicated results in this month’s newsletter tackle aging, a purported pathway for oxytocin’s effects on autistic people, and a possible autism biomarker.
Spectrum: Autism Research News
Tag: null and noteworthy
This month, a commonly used emotion-recognition test doesn’t perform as expected — nor does a survey of past efforts to train autism specialists or a hunt for the sources of the sleep problems that often accompany the condition.
This month, we pore over null results from a study of the accuracy of emotion recognition skills in autistic people, clinical trials of a vasopressin drug called balovaptan, and an analysis of ‘systemizing’ abilities in autistic children.
In this edition, researchers sink a purported link between cerebellar volume and autism and buoy a theory about measuring social behaviors.
In this edition, a strategy to help autistic children adapt their skills to new situations shows no benefit, but an early-life autism biomarker does.
In this edition of Null and Noteworthy, a large clinical trial goes sideways, while memory and emotions hold up.
In this edition of Null and Noteworthy, researchers replicate encouraging findings on autism and aging and shoot down a host of potential links between pregnancy complications and having a child with autism.
In this edition of Null and Noteworthy, the Interagency Autism Coordinating Committee grapples with “groundbreaking” research and two reviews of interventions come to conflicting conclusions.
In this edition of Null and Noteworthy, tests of intranasal oxytocin and an Angelman syndrome treatment fail to see results.